KEZAR LIFE SCIENCES INC

$5.49 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About KEZAR LIFE SCIENCES INC

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company is developing small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single. The Company's product portfolio includes KZR-616 and KZR-261. The KZR-616 is a selective immunoproteasome inhibitor being evaluated in Phase II clinical trials in lupus nephritis, dermatomyositis, and polymyositis. In addition, KZR-261 is an anti-cancer clinical candidate targeting the Sec61 translocon and the protein secretion pathway. The Company is focusing its initial development of KZR-616 in severe, chronic and orphan immune-mediated diseases. The Company’s principal operations are in South San Francisco, California.

Stock Analysis

last close $5.9
1-mo return -59.5%
3-mo return -58.8%
avg daily vol. 1.49M
52-week high 18.55
52-week low 4.61
market cap. $347M
forward pe -
annual div. -
roe -30.9%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 75.2%
baraka

Subscribe now for daily local and international financial news

Subscribe